Venus Medtech-B (02500.HK): Releases Further Announcement in Respect of U.S. Patent Infringement Litigation

Venus Medtech (Hangzhou) Inc. (02500.HK) released an announcement on the noon of January 22, providing further information in relation to a patent infringement litigation involving the U.S. market.

The announcement disclosed that Cardiovalve Ltd. and MTH IP, L.P. filed a lawsuit against Edwards Lifesciences Corp. and its affiliated companies with the United States District Court for the District of Delaware on January 14, 2026. The litigation alleges that Edwards' core product, the PASCAL Precision Transcatheter Valve Repair System, has infringed U.S. Patent No. 10,702,385 held by Cardiovalve Ltd..

The validity of the aforesaid patent was confirmed by the United States Court of Appeals for the Federal Circuit on June 9, 2025, which rejected the challenge previously raised by Edwards.

At present, the litigation is still at the preliminary stage. Further details, including the potential amount of compensation claimed, will be subject to the outcome of the litigation. The Company stated that it will make further announcements on any material developments of the litigation in a timely manner in accordance with the Hong Kong Listing Rules.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.